Sex: F
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: The patient took the third dose of Vivotif with a delay of approximately 22 hours; Case reference number US-BN-2023-010729 is a spontaneous case initially received from a healthcare professional via agency (reference number USBAV23-2155) on 22-Dec-2023 and concerns a 39-year-old female patient.  The patient's current condition included seasonal allergies.  The patient's concomitant medications included sodium (brand name: unknown), vitamin D (brand name: unknown), and Claritin (loratadine).  On 17-Dec-2023, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, orally, for immunization against disease caused by Salmonella typhi.  On 19-Dec-2023, two days after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, orally.  On 22-Dec-2023, three days after the second dose of Vivotif, reported as taken with a delay of approximately 22 hours, the patient took the third dose of Vivotif (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered').   It was confirmed that the patient did not experience any adverse events due to the Vivotif vaccination.  *Additional information received from a healthcare professional via agency (reference number: USBAV23-2168) on 22-Dec-2023: New information included additional reporter details, and reference numbers (EMG2023-2524).*  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from the reporter on 11-Jan-2024: New information included additional patient details, medical history and concomitant medications, dosage details for the vaccination with Vivotif, confirmation that delay in administration was during the third dose, confirmation that the patient took three doses of Vivotif, confirmation about deviations or issues during the administration and that the patient did not experience any adverse event due to Vivotif vaccine.  Follow-up information received from the reporter on 07-Feb-2024: New information included that the case was identified as a duplicate of US-BN-2023-010733 and information from US-BN-2023-010733 was merged into the case US-BN-2023-010729, incomplete course of vaccination and missed dose were removed.  The report initially received on 22-Dec-2023 (reference number: USBAV23-2168) did not contain the criteria required for the identification of duplicate reports.; Reporter's Comments: A 39-year-old female patient took the third dose of Vivotif on the day 3 after the second dose, reported as taken with a delay of approximately 22 hours, which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. The patient did not experience any adverse event due to Vivotif vaccine. The patient's medical history included seasonal allergies, and concomitant medications included sodium, vitamin D and Claritin. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 39-year-old female patient took the third dose of Vivotif on the day 3 after the second dose, reported as taken with a delay of approximately 22 hours, which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. The patient did not experience any adverse event due to Vivotif vaccine. The patient's medical history included seasonal allergies, and concomitant medications included sodium, vitamin D and Claritin. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.